Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Deferred Tax Liability (2020 - 2025)

Oncology Institute (TOI) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with $32000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $32000.0, compared with a TTM value of $32000.0 through Mar 2025, changed 0.0%, and an annual FY2024 reading of $32000.0, down 99.69% over the prior year.
  • Non-Current Deferred Tax Liability was $32000.0 for Q1 2025 at Oncology Institute, roughly flat from $32000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $10.2 million in Q4 2023 and bottomed at $32000.0 in Q1 2024.
  • Average Non-Current Deferred Tax Liability over 5 years is $912428.6, with a median of $95000.0 recorded in 2022.
  • The sharpest move saw Non-Current Deferred Tax Liability surged 9353.7% in 2023, then tumbled 99.69% in 2024.
  • Year by year, Non-Current Deferred Tax Liability stood at $371000.0 in 2021, then plummeted by 70.89% to $108000.0 in 2022, then soared by 9353.7% to $10.2 million in 2023, then crashed by 99.69% to $32000.0 in 2024, then changed by 0.0% to $32000.0 in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for TOI at $32000.0 in Q1 2025, $32000.0 in Q4 2024, and $32000.0 in Q3 2024.